Silencing of the CD24-Siglec-E pathway could deteriorate the diet-induced metabolic disorders, including obesity, dyslipidemia, insulin resistance, and nonalcoholic steatohepatitis (NASH), which could be alleviated by CD24Fc treatment (14). This evidence concerns the gene CD24 and obesity disorder.